Please login to the form below

Not currently logged in
Email:
Password:

Stallergenes appoints Christian Chavy CEO

He will replace Roberto Gradnik at the end of this month

Christian Chavy has been appointed CEO of French biopharmaceutical company Stallergenes and will take over from Roberto Gradnik at the end of this month.  

Chavy has worked for the ARES Life Science healthcare investment fund since 2010 and prior to that he served as president of global operations for Actelion Pharmaceuticals.  

Before joining Actelion he was vice president of Serono's reproductive medicine strategic unit and chairman of the company's French subsidiary.

Stallergenes said Chavy's appointment would enable it to “pursue its strategy” and to its work in promising immunotherapy markets – the US in particular.  

Meanwhile Gradnick, who joined Stallergenes in October 2011 as deputy CEO before taking up the post of CEO three months later, will provide consultancy services to the board of directors during a four-month transitional period.

7th March 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics